SuperworthMerck MRK
- Market cap
- $358.4B
- PE
- 116×
- 10y median 24.9×
- Forward PE
- 17.5×
- 10y median 16.6×
- Price to sales
- 5.4×
- EV/EBIT
- 20.4×
- Revenue, 12 months
- $66.6B
- +5% on a year ago
- Net margin
- 4.8%
- Free cash flow yield
- 4.5%
Merck trades at 116× trailing earnings, pricier than 93% of the last ten years. Revenue was $66.6B over the last twelve months, up 5% on a year earlier with a 5% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $16B+7% | $14.6B+6% | $15.8B+9% | $16.1B+7% | $16.7B+4% | $15.6B+7% | $15.5B−2% | $15.8B−2% | $17.3B+4% | $16.4B+5% | $16.3B+5% | $16.6B+5% | |
| Cost of revenue | $4.3B+8% | $3.9B+1% | $3.5B−10% | $3.7B−7% | $4.1B−4% | $3.8B−2% | $3.4B−3% | $3.6B−5% | $3.9B−6% | $5.6B+45% | $4.2B+23% | $4.4B+24% |
| Gross profit | $11.7B+6% | $10.7B+8% | $12.2B+16% | $12.4B+12% | $12.6B+8% | $11.8B+10% | $12.1B−1% | $12.2B−1% | $13.4B+7% | $10.8B−8% | $12.1B−0% | $12.2B−0% |
| R&D | $3.3B−25% | $9.6B+155% | $4B−7% | $3.5B−74% | $5.9B+77% | $4.6B−52% | $3.6B−9% | $4B+16% | $4.2B−28% | $3.9B−15% | $12.6B+248% | $9.7B+141% |
| SG&A | $2.5B+0% | $2.8B+4% | $2.5B+0% | $2.7B+1% | $2.7B+8% | $2.9B+2% | $2.6B+3% | $2.6B−3% | $2.6B−4% | $2.9B+1% | $2.7B+6% | $2.9B+10% |
| $5.7B+43% | −$2B | $5.6B+51% | $6B | $3.9B−32% | $4.3B | $5.9B+4% | $5B−18% | $6.5B+66% | $3.9B−10% | −$3.4B | −$584M | |
| Interest expense | $317M+30% | $310M+32% | $303M+25% | $310M+12% | $330M+4% | $328M+6% | $313M+3% | $305M−2% | $327M−1% | $411M+25% | $479M+53% | $525M+72% |
| Pre-tax income | $5.6B+57% | −$2B | $5.7B+55% | $6B | $4.1B−27% | $4.2B | $5.9B+4% | $5B−17% | $6.7B+65% | $3.4B−18% | −$3.5B | −$683M |
| $870M+164% | −$820M | $903M+10% | $545M−14% | $929M+7% | $426M | $818M−9% | $571M+5% | $958M+3% | $458M+8% | $709M−13% | $654M+15% | |
| Net income | $4.7B+46% | −$1.2B | $4.8B+69% | $5.5B | $3.2B−34% | $3.7B | $5.1B+7% | $4.4B−19% | $5.8B+83% | $3B−21% | −$4.2B | −$1.3B |
| $1.86+45% | −$0.48 | $1.87+69% | $2.14 | $1.24−33% | $1.48 | $2.01+8% | $1.76−18% | $2.32+87% | $1.19−20% | −$1.72 | −$0.54 | |
| 2.5B+0% | 2.5B−1% | 2.5B−0% | 2.5B+0% | 2.5B−0% | 2.5B+0% | 2.5B−1% | 2.5B−1% | 2.5B−2% | 2.5B−2% | 2.5B−2% | 2.5B−2% |
Gross profit: 71 periods, Q2 FY08 to Q2 FY26: not printed by the filing, worked out from its own lines.
Operating income: 71 periods, Q2 FY08 to Q2 FY26: not printed by the filing, worked out from its own lines.
Net income: Q3 FY09: the year less its other three quarters as the newest filings print them. 15 periods, Q4 FY09 to Q4 FY25: printed in the fourth-quarter results release.
EPS, diluted: 15 periods, Q4 FY09 to Q4 FY25: printed in the fourth-quarter results release. Q4 FY16 and Q4 FY17: quarter's net income to common over its shares, to the cent.
Diluted shares: 15 periods, Q4 FY09 to Q4 FY25: printed in the fourth-quarter results release. Q4 FY16 and Q4 FY17: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q3 FY26 | $17.3B | $17.3B to $17.4B | $2.09 | $1.99 to $2.17 | 12 |
| Q4 FY26 | $16.8B | $16.6B to $17B | $1.95 | $1.82 to $2.07 | 10 |
| Q1 FY27 | $16.5B | $16.3B to $16.8B | $2.14 | $2.10 to $2.18 | 8 |
| Q2 FY27 | $17B | $16.8B to $17.3B | $2.14 | $2.10 to $2.18 | 8 |
| Q3 FY27 | $18.2B | $17.9B to $18.5B | $2.40 | $2.35 to $2.45 | 8 |
| Q4 FY27 | $17.8B | $17.6B to $18.1B | $2.17 | $2.13 to $2.21 | 8 |
| Q1 FY28 | $17.4B | $17.2B to $17.7B | $2.23 | $2.19 to $2.28 | 9 |
| Q2 FY28 | $17.9B | $17.7B to $18.2B | $2.25 | $2.21 to $2.30 | 9 |
Peers
Companies in Drug Manufacturers - General nearest Merck's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| MRKMerck | $358.4B | 116× | 24.9× | 17.5× | 5.4× | +5% | 4.8% |
| ABBVAbbVie | $504.8B | 80.7× | 27.9× | 19.0× | 7.8× | +10% | 9.8% |
| AMGNAmgen | $237.5B | 27.3× | 21.1× | 18.6× | 6.2× | +9% | 23.0% |
| JNJJohnson & Johnson | $635.8B | 40.0× | 24.3× | 23.4× | 6.4× | +8% | n/m |
| GILDGilead Sciences | $193.5B | n/m | 18.8× | 17.2× | 6.4× | +6% | −10.6% |
| PFEPfizer | $171.2B | 39.5× | 15.8× | 10.9× | 2.7× | −0% | 6.8% |
| BMYBristol-Myers Squibb | $125.6B | 13.5× | 19.9× | 10.4× | 2.6× | +3% | 18.9% |
| LLYEli Lilly and | $1.2T | 42.7× | 41.4× | 33.9× | 15.0× | +50% | 33.5% |
| BIIBBiogen | $37B | 44.4× | 16.1× | 19.1× | 3.7× | +0% | 8.3% |
| Peer median | $215.5B | 40.0× | 20.5× | 18.8× | 6.3× | +7% | 9.8% |
Investors who own it
Investors we follow who held Merck at the end of Jun 30, 2026, from their 13F filings.
- Bill NygrenHarris Associates (Oakmark)2.1% of portfoliotrimmed
- Chris BloomstranSemper Augustus0.6% of portfolio
- Ron BaronBaron Capital0.0% of portfoliotrimmed
- Tom RussoGardner Russo & Quinn0.0% of portfoliotrimmed
More on Merck
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Dividend yield
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #1of 34Healthcare stocks with the lowest PEG ratio
- #8of 33Healthcare stocks with the highest dividend yields
Its groups
About
- Chief executive
- Rob Davis, since 2021Joined 2014 as CFO, CEO since 2021. Source
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .